At the 2026 American Academy of Dermatology meeting, Kenvue (KVUE) used its Neutrogena, Aveeno and Rogaine brands to spotlight new products and clinical data, a move that has put fresh attention on the stock.
See our latest analysis for Kenvue.
The new dermatology data arrives as Kenvue’s 90 day share price return of 3.57% contrasts with a 1 year total shareholder return decline of 16.87%, suggesting recent momentum has picked up after a weaker stretch.
If this kind of product led story has your attention, it could be a good moment to broaden your watchlist with consumer focused names using the 19 top founder-led companies
With Kenvue trading at US$17.43, sitting about 13% below the average analyst price target and with an estimated 39% intrinsic discount, the key question is whether this reflects mispricing or if the market already anticipates future growth.
Most Popular Narrative: 30.5% Undervalued
According to a widely followed narrative on Kenvue, the fair value sits at $25.09 versus the last close of $17.43, which frames the current discount in a very different light.
Macro drivers like an aging population and premiumization of health care will act as tailwinds for all of Kenvue ’ s brands.
Curious what kind of revenue path, margin profile and future earnings multiple could justify that higher fair value on a consumer health name built around megabrands?
Result: Fair Value of $25.09 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this upbeat view still faces pressure from rising input costs that may squeeze pricing power, as well as ongoing talc related reputational issues around the Johnson’s brand.
Find out about the key risks to this Kenvue narrative.
Another Take On Kenvue’s Valuation
Those fair value estimates based on future cash flows tell one story, but the P/E ratio tells another. Kenvue trades at 22.7x earnings, above both the peer average of 17.6x and the global industry at 19.1x, and even above a fair ratio of 19.8x, which points to valuation risk if sentiment cools.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With mixed signals on value and sentiment throughout this article, it makes sense to look at the numbers yourself and move quickly to form your own stance, then weigh up the 3 key rewards and 2 important warning signs
Looking for more investment ideas?
If Kenvue is already on your radar, do not stop there. Broaden your opportunity set with other stock ideas before the market prices them in.
- Target reliable income by reviewing a curated set of higher yielding names through the 11 dividend fortresses.
- Spot potential bargains early by scanning companies that pair quality with attractive pricing using the 62 high quality undervalued stocks.
- Prioritize capital preservation by focusing on companies that score well on financial resilience with the 73 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com